Krebs Biochemicals & Industries (BSE:524518) - Share price, News & Analysis

524518 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

524518 Stock Overview

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India.

Risk Analysis

Earnings have declined by 19.3% per year over past 5 years

Has less than 1 year of cash runway

Negative shareholders equity

Does not have a meaningful market cap (₹2B)

Krebs Biochemicals & Industries Competitors

Ambalal Sarabhai Enterprises

BSE:500009

₹2.4b

Kilitch Drugs (India)

BSE:524500

₹2.8b

Wanbury

BSE:524212

₹2.2b

Panchsheel Organics

BSE:531726

₹2.1b

Price History & Performance

Summary of all time highs, changes and price drops for Krebs Biochemicals & Industries
Historical stock prices
Current Share Price	₹103.40
52 Week High	₹227.95
52 Week Low	₹96.00
Beta	0.49
1 Month Change	-8.90%
3 Month Change	-39.28%
1 Year Change	-11.17%
3 Year Change	37.87%
5 Year Change	0.83%
Change since IPO	-62.15%

Shareholder Returns

	524518	IN Pharmaceuticals	IN Market
7D	-2.6%	0.4%	0.08%
1Y	-11.2%	-16.7%	-0.1%

Return vs Industry: 524518 exceeded the Indian Pharmaceuticals industry which returned -16.7% over the past year.

Return vs Market: 524518 underperformed the Indian Market which returned -0.1% over the past year.

Price Volatility

Is 524518's price volatile compared to industry and market?
524518 volatility
524518 Average Weekly Movement	7.4%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	6.8%
10% most volatile stocks in IN Market	9.8%
10% least volatile stocks in IN Market	4.4%

Stable Share Price: 524518 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 524518's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1991	390	Pabitra Kumar Bhattacharya	https://krebsbiochem.com

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications.

Krebs Biochemicals & Industries Fundamentals Summary

How do Krebs Biochemicals & Industries's earnings and revenue compare to its market cap?
524518 fundamental statistics
Market Cap	₹2.23b
Earnings (TTM)	-₹445.27m
Revenue (TTM)	₹597.03m

3.7x

P/S Ratio

-5.0x

P/E Ratio

Is 524518 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
524518 income statement (TTM)
Revenue	₹597.03m
Cost of Revenue	₹737.00m
Gross Profit	-₹139.97m
Other Expenses	₹305.30m
Earnings	-₹445.27m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-20.65
Gross Margin	-23.44%
Net Profit Margin	-74.58%
Debt/Equity Ratio	-190.3%

How did 524518 perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is 524518 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524518?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 524518. This is calculated by dividing 524518's market cap by their current preferred multiple.
What is 524518's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	₹2.23b

524518 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.1x
Enterprise Value/EBITDA	-11.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 524518's PS Ratio compare to its peers?

524518 PS Ratio vs Peers

The above table shows the PS ratio for 524518 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	1.8x
500009 Ambalal Sarabhai Enterprises	1.2x	n/a	₹2.4b
524500 Kilitch Drugs (India)	2.4x	n/a	₹2.8b
524212 Wanbury	0.4x	n/a	₹2.2b
531726 Panchsheel Organics	3.1x	n/a	₹2.1b
524518 Krebs Biochemicals & Industries	3.7x	n/a	₹2.2b

Forward PS

Price-To-Sales vs Peers: 524518 is expensive based on its Price-To-Sales Ratio (3.7x) compared to the peer average (1.8x).

Price to Earnings Ratio vs Industry

How does 524518's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Sales vs Industry: 524518 is expensive based on its Price-To-Sales Ratio (3.7x) compared to the Indian Pharmaceuticals industry average (1.7x)

Price to Sales Ratio vs Fair Ratio

What is 524518's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524518 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 524518's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 524518 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 524518's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 524518's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524518's PEG Ratio to determine if it is good value.

Discover undervalued companies

Take a look at our analysis of 524518's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Krebs Biochemicals & Industries regulatory filings.

Future Growth

How is Krebs Biochemicals & Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

23.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Krebs Biochemicals & Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Take a look at our analysis of 524518’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
Krebs Biochemicals & Industries competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Krebs Biochemicals & Industries performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-19.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524518 is currently unprofitable.

Growing Profit Margin: 524518 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 524518 is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.

Accelerating Growth: Unable to compare 524518's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 524518 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).

Return on Equity

High ROE: 524518's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Discover strong past performing companies

Financial Health

How is Krebs Biochemicals & Industries's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 524518 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 524518 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: 524518 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 524518's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 524518 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 524518 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.6% each year

Discover healthy companies

Dividend

What is Krebs Biochemicals & Industries's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 524518's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524518's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524518's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524518's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 524518 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure

CEO

Pabitra Kumar Bhattacharya (53 yo)

0.92

Tenure

Mr. Pabitra Kumar Bhattacharya has been Managing Director of Krebs Biochemicals & Industries Limited since August 1, 2021 and has been its Additional Director since July 30, 2021. Mr. Bhattacharya serves a...

Leadership Team

Experienced Management: 524518's management team is considered experienced (2.3 years average tenure).

Board Members

Experienced Board: 524518's board of directors are considered experienced (7.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/07/06 00:00
End of Day Share Price	2022/07/06 00:00
Earnings	2022/03/31
Annual Earnings	2022/03/31